Stereotaxis
    Print Page  Close Window
S-1/A
STEREOTAXIS, INC. filed this Form S-1/A on 05/12/2004
Entire Document
 << Previous Page | Next Page >>
<PAGE>


7.2.2    [***]

7.2.3    [***]

7.2.4    [***]

7.2.5    [***]

7.2.6    [***]

7.3      Discounting. Biosense agrees that for computations made under
         Paragraphs 7.1 and 7.2 hereunder, the average discount applied to the
         list price for the sale of all Daughter Products in any given year will
         not exceed the average discount to the list price for corresponding
         Parent Products during the same period.

7.4      Exchange Rates. If any currency conversion is required to calculate the
         sales applied against the Net Revenue for Daughter Products, such
         conversion will be made by using the exchange rates used by Biosense in
         calculating Biosense's own revenues for financial reporting purposes in
         the United States in accordance with U.S. GAAP. If any currency
         conversion is required to calculate the Cost of Goods for Daughter
         Products, such conversion will be made by using the exchange rates used
         by Stereotaxis in calculating Stereotaxis's own costs for financial
         reporting purposes in the U.S. accordance with U.S. GAAP.

7.5      Payment. Biosense will pay Stereotaxis the applicable Revenue Share on
         a quarterly basis within thirty (30) days of the end of each quarter.
         With each such payment Biosense will include a report that sets forth
         in sufficient detail. the manner in which Biosense calculated the
         Revenue Share for the applicable quarter. All payments will be made in
         US Dollars($).

7.6      Annual Biosense Reports and Audits.

7.6.1    Reports. Within sixty (60) days after the end of each calendar year,
         Biosense will provide a report to Stereotaxis which sets forth: the
         Gross Profits and Cost of Goods, for Daughter Products sold (including
         the calculation thereof), and any difference in the Revenue Share 


[*** Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.]

                                       25

 << Previous Page | Next Page >>